Alison H. Thomson

Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee.

P. Vasey, Stan B. Kaye, Rachel Morrison et al. · PubMed · 1999 · 691 citations

Pathology, Pharmacotherapy, Maximum Tolerated Dose +16

Cost-Effectiveness of Therapeutic Drug Monitoring

Daan J. Touw, Cees Neef, Alison H. Thomson et al. · Therapeutic Drug Monitoring · 2005 · 205 citations

Increase in emergency admissions to hospital for children aged under 15 in England, 1999-2010: national database analysis

P. J. Gill, Michael J Goldacre, David Mant et al. · Archives of Disease in Childhood · 2013 · 184 citations · Full text

Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations

Alison H. Thomson, Christine E. Staatz, C. M. Tobin et al. · Journal of Antimicrobial Chemotherapy · 2009 · 140 citations · Full text

External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings

Wei Zhao, Florentia Kaguelidou, Valérie Biran et al. · British Journal of Clinical Pharmacology · 2012 · 112 citations · Full text